Pfizer reported a strong quarterly performance, raising its revenue guidance to $61.5 billion driven by a robust non-COVID product portfolio and recent acquisitions. The company is implementing operational efficiency programs aimed at saving $9.7 billion by 2029, which will support continued R&D investment, debt reduction, and a healthy 6.22% dividend yield. Despite risks from loss of exclusivity (LOE), Pfizer’s valuation remains attractive with upside potential if its pipeline and cost-saving initiatives succeed. The stock is rated a Buy based on these fundamentals and growth strategies post-LOE.
Pfizer shares trade at USD 27.73 on Pluang as of Sep 22, 2026 23:03 WIB, close to its 52-week high of USD 29.02 and well above the 52-week low of USD 23.60. The stock offers a strong dividend yield of 6.2%, aligning closely with the article's mention of 6.22%. Pluang data shows a balanced order activity with 51% buying interest, reflecting steady investor engagement despite a slight 1-day price dip of 0.04%.
Pfizer has been downgraded from Buy to Hold following a roughly 20% total return since last October. The analyst notes that the stock's valuation, currently around 8.7 times EV/EBITDA, offers less downside protection, and near-term earnings visibilit...
Pfizer remains an attractive income stock, yielding 6.22% and trading at 9.3 times the 2026 expected earnings per share. Its non-COVID business is growing operationally by 5%, supported by a strong pipeline and $1.5 billion ahead of its 2026 business...
Pfizer has paused its annual dividend increase for the first time in over a decade, maintaining a quarterly payout of $0.43 throughout 2026. This pause comes despite a strong 6.2% dividend yield and solid adjusted earnings coverage, reflecting cautio...
